Therapeutic antibodies that block the programmed death-1 (PD-1)programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer 1-5 . However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent (atezolizumab) and identified major determinants of clinical outcome. Response to treatment was associated with CD8 + T-effector cell phenotype and, to an even greater extent, high neoantigen or tumour mutation burden. Lack of response was associated with a signature of transforming growth factor β (TGFβ) signalling in fibroblasts. This occurred particularly in patients with tumours, which showed exclusion of CD8 + T cells from the tumour parenchyma that were instead found in the fibroblast-and collagen-rich peritumoural stroma; a common phenotype among patients with metastatic urothelial cancer. Using a mouse model that recapitulates this immune-excluded phenotype, we found that therapeutic co-administration of TGFβ-blocking and anti-PD-L1 antibodies reduced TGFβ signalling in stromal cells, facilitated T-cell penetration into the centre of tumours, and provoked vigorous anti-tumour immunity and tumour regression.
Therapeutic antibodies that block the programmed death-1 (PD-1)programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer
. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent (atezolizumab) and identified major determinants of clinical outcome. Response to treatment was associated with CD8 + T-effector cell phenotype and, to an even greater extent, high neoantigen or tumour mutation burden. Lack of response was associated with a signature of transforming growth factor β (TGFβ) signalling in fibroblasts. This occurred particularly in patients with tumours, which showed exclusion of CD8 + T cells from the tumour parenchyma that were instead found in the fibroblast-and collagen-rich peritumoural stroma; a common phenotype among patients with metastatic urothelial cancer. Using a mouse model that recapitulates this immune-excluded phenotype, we found that therapeutic co-administration of TGFβ-blocking and anti-PD-L1 antibodies reduced TGFβ signalling in stromal cells, facilitated T-cell penetration into the centre of tumours, and provoked vigorous anti-tumour immunity and tumour regression. Integration of these three independent biological features provides the best basis for understanding patient outcome in this setting and suggests that TGFβ shapes the tumour microenvironment to restrain anti-tumour immunity by restricting T-cell infiltration.
Pre-treatment tumour samples from a large phase 2 trial (IMvigor210) investigating the clinical activity of PD-L1 blockade with atezolizumab in metastatic urothelial cancer (mUC) were used for an integrated evaluation of biomarkers (Extended Data Fig. 1a ; Supplementary Discussion). We categorized patients who responded to treatment with a complete or partial response as responders and compared them with non-responders, who displayed stable or progressive disease. As previously reported 2, 4 , PD-L1 expression on immune cells (more than 5% of immune cells in mUC are detected by the PD-L1 antibody SP142) was significantly associated with response ( Fig. 1a ). By contrast, PD-L1 expression on tumour cells was not associated with response (Extended Data Fig. 1b ). We next performed transcriptome RNA sequencing (RNA-seq) in 298 tissue samples and assessed correlations with PD-L1 expression on immune cells and response. A gene set associated with CD8 + T-effector (T eff ) cells 4, 5 was highly correlated with PD-L1 expression on immune cells (Extended Data Fig. 1c, d ; Supplementary Discussion). This gene set was also significantly associated with response, particularly with complete response, and with overall survival (Fig. 1b, c) .
mUC is characterized by one of the highest somatic mutation rates 6, 7 . In mUC, tumour mutation burden (TMB) correlates with response to immune checkpoint inhibitors 4, 5 . We confirmed these findings ( Fig. 1d, e ) and showed that computationally predicted tumour neoantigen burden behaved similarly (Extended Data Fig. 1e, f ), suggesting that the TMB reflects an increased potential for immunogenicity [8] [9] [10] [11] . We next assessed the transcriptional and mutational correlates of TMB in mUC. The pathways that were most significantly associated with TMB were those involved in the cell cycle, DNA replication and DNA damage response (DDR; Extended Data Fig. 1g ; Supplementary Table 1 ). Signatures for these pathways were correlated with MKI67 and thus with proliferation (Extended Data Fig. 1h ). Expression levels of APOBEC3A and APOBEC3B, which encode two cytidine deaminases that are upregulated in urothelial and other cancers 12, 13 , were also correlated with TMB and response (Extended Data Fig. 1i , j; Supplementary  Tables 2, 3 ). Finally, tumours with one or more mutations in DDR or cell cycle regulator gene sets had significantly higher TMB and response rates ( Fig. 1f , g; Extended Data Fig. 1k , l; Supplementary Tables 4, 5 ).
Next, we investigated features beyond CD8 + T-cell immunity and TMB that we associated with response. Gene set enrichment analysis identified the cytokine-cytokine-receptor gene set as the only feature associated with non-response (Extended Data Fig. 2a ; Supplementary  Table 6 ). The most significantly associated genes within this pathway were IFNGR1 and genes involved in the TGFβ signalling pathway: TGFB1, ACVR1 and TGFBR2 (Supplementary Table 3 ). Whereas IFNγ is known to have favourable effects on anti-tumour immunity, persistent signalling by this cytokine has been associated with adaptive resistance to checkpoint therapy [14] [15] [16] [17] . We observed significantly enhanced expression of IFNG in responders, whereas IFNGR1 expression was significantly higher in non-responders (Extended Data Fig. 2b, c) . TGFβ is a pleiotropic cytokine that is associated with poor prognosis in multiple tumour types [18] [19] [20] and is thought to have a protumorigenic role in advanced cancers by promoting immunosuppression, angiogenesis, metastasis, tumour cell epithelial-to-mesenchymal transition (EMT), fibroblast activation and desmoplasia 19, [21] [22] [23] . The two top-scoring TGFβ pathway genes in our data represent a TGFβ ligand, TGFB1, and a TGFβ receptor, TGFBR2. Both showed increased mean expression in non-responders and association with reduced overall survival ( Fig. 1h , i; Extended Data Fig. 2d, e ). Taken together, these results suggest that the impact of checkpoint inhibition on patient outcome in mUC is dictated by three core biological pathways: (i) pre-existing T-cell immunity and (ii) TMB are positively associated with outcome, whereas (iii) TGFβ is associated with lack of response and reduced survival ( Fig. 1j ).
Most human solid tumours exhibit one of three distinct immunological phenotypes: immune inflamed, immune excluded, or immune desert 1, 24 . Previous evidence, mostly from melanomas, has suggested that inflamed tumours are the most responsive to checkpoint blockade 24, 25 , but the relevance of the tumour-immune phenotype to the response of mUCs was previously unknown. In our mUC cohort, a large proportion of tumours (47%) exhibited the excluded phenotype; by contrast, only 26% and 27% of tumours exhibited the inflamed and desert phenotypes, respectively ( Fig. 2a, b ; Extended Data Fig. 2f ). The mean signal for the CD8 + T eff signature was lowest in the desert phenotype, intermediate in the excluded phenotype and highest in inflamed tumours (Fig. 2c) , and was significantly associated with response only in inflamed tumours, consistent with a model in which the absence of CD8 + T cells, or their spatial separation from tumour cells, makes the signature irrelevant.
The observed proximity of CD8 + T cells to desmoplastic stroma in immune-excluded tumours ( Fig. 2a ; Extended Data Fig. 2f ) suggests that the relevance of TGFβ in this phenotype may be driven by its impact on stromal cells. To measure TGFβ pathway activity specifically in fibroblasts, we generated a pan-fibroblast TGFβ response signature (F-TBRS). Average expression of this signature was low in immune deserts but significantly higher in inflamed and excluded tumours.
Consistent with a role for TGFβ pathway activation in fibroblasts in the tumour microenvironment (TME), the F-TBRS was significantly associated with non-response only in excluded tumours ( Fig. 2d ). TMB was significantly associated with response in both excluded and inflamed tumours ( Fig. 2e ).
To better understand how the three core pathways relate to one another and to measure the relative strengths of their association with outcome, we performed a statistical analysis of competing models. Logistic regression pseudo-R 2 was used as a measure of 'explained variance' in patient response 26 .
In immune desert tumours, the pathways showed negligible explanatory power ( Fig. 2f ). For excluded tumours, both the F-TBRS signature and TMB were significantly associated with response, and combining the two provided a significant improvement over either term in isolation. By contrast, in inflamed tumours, the CD8 + T eff signature combined with TMB exhibited the strongest correlation with response. In an analysis in which all the samples were combined, a model incorporating the three core pathways significantly improved on all single-and two-pathway models ( Fig. 2f ; Extended Data Fig. 2g ), demonstrating that the information provided by each pathway is at least partially independent.
The Cancer Genome Atlas (TCGA) molecular-subtype taxonomy 12 has been widely investigated with respect to mUC, but with inconsistent results. Here we contrast the TCGA taxonomy with the Lund taxonomy, which includes a genomically unstable subtype 27, 28 (Extended Data Fig. 3 ). Consistent with the importance of TMB, we observed that the genomically unstable subtype was significantly enriched for response ( Fig. 3 ). This effect could not, however, be attributed to TMB alone, as the TCGA luminal II subtype was similarly enriched for high-TMB tumours (Extended Data Fig. 4a, b ). Instead, we identified the source 
TMB:
DDR gene mutation prevalence Figure 1 | Three core biological pathways are associated with response to atezolizumab. a, PD-L1 on immune cells is associated with response (two-sided Fisher's exact test P = 0.0038). IC2/3 tumours had a significantly higher complete response (CR) rate (P = 0.0006). PD, progressive disease; SD, stable disease; PR, partial response. PD-L1 expression on immune cells (IC) is assessed by SP142 immunohistochemistry assay and scored as IC0 (< 1%), IC1 (≥ 1% and < 5%), or IC2/3 (≥ 5%). b, CD8 + T eff -signature score is positively associated with response (two-tailed t-test, P = 0.0087), with association driven by the complete response group (CR versus PR, P = 0.0388; CR versus SD, P = 0.0668; CR versus PD, P = 0.0003). c, CD8 + T eff -signature quartiles are significantly associated with overall survival (likelihood ratio test, P = 0.0092). d, e, TMB is positively associated with response to atezolizumab (two-tailed t-test, P = 6.9 × 10 −7 ) and overall survival (likelihood ratio test, P = 2.0 × 10 −5 ). A similar plot for tumour neoantigen burden is shown in Extended Data Fig. 1e , f. f, g, There is a significant association between DDR mutation status and response (f; twosided Fisher's exact test, P = 0.0117 excluding TP53) and TMB (g), both with (two-sided Fisher's exact test, P = 6.01 × 10 −8 ) and without inclusion of TP53 (P = 1.95 × 10 −5 ). h, i, TGFB1 gene expression is significantly associated with non-response (two-tailed t-test, P = 0.00011) and reduced overall survival (likelihood ratio test, P = 0.0096). j, The relationship between response and three core biological pathways. #P < 0.10, * P < 0.05, * * P < 0.01, *** P < 0.001. Sample sizes are given in parentheses. Q1-Q4, quartiles, lowest to highest. Box plots show median, whiskers represent minimum and maximum excluding outliers, and circles are outliers.
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of the difference by separately evaluating patients classified as TCGA luminal II only, Lund genomically unstable only, or both (Extended Data Fig. 4c ). Among these groups, genomically unstable-only tumours had the lowest CD8 + T eff signature scores and lowest TMB, but responded favourably; by contrast, luminal II-only tumours showed sharply increased F-TBRS scores and responded poorly (Extended Data Fig. 4d , e). These results demonstrate the importance of interactions among the three core pathways in determining response. The Lund subtypes are discussed further in the Supplementary Discussion.
To test our hypothesis that physical exclusion of T cells by the stromal barrier limits response to atezolizumab in immune-excluded tumours, we studied the EMT6 mouse mammary carcinoma model to determine whether there is a role for TGFβ -activated stroma in this context. The EMT6 model exhibits the immune-excluded phenotype (Extended Data Fig. 5a-d ) and expresses all TGFβ isoforms as well as PD-L1 (Extended Data Fig. 5e , f). Although therapeutic blockade of PD-L1 or TGFβ alone had little or no effect, mice treated with antibodies against both PD-L1 and TGFβ exhibited a significant reduction in tumour burden ( Fig. 4a, b ; Extended Data Fig. 5g , h). Regression of EMT6 tumours in these studies was completely dependent on CD8 + T cells (Extended Data Fig. 5i ). These findings were reproduced in a second relevant mouse tumour model, MC38 (Extended Data Fig. 5j -n).
Combined antibody blockade also led to a significant increase in tumour-infiltrating T cells (Extended Data Fig. 6a ), particularly CD8 + T eff cells ( Fig. 4c, d ; Extended Data Fig. 6b ). Blockade of TGFβ , alone or in combination with anti-PD-L1, had no effect on the number of CD4 + T-regulatory (T reg ) cells in the tumour (Extended Data Fig. 6c-e ). RNAseq data revealed that the CD8 + T eff signature was increased in mouse tumours treated with a combination of anti-PD-L1 and anti-TGFβ ( Fig. 4e ). Quantitative histopathology demonstrated that T cell . Rare CD8 + T cells are interspersed between tumour cells (green arrows). b, Distribution of tumour-immune phenotypes in IMvigor210. c, CD8 + T eff score is significantly associated with response only in the inflamed phenotype (two-tailed t-test, P = 0.042). d, F-TBRS is significantly associated with response only in the excluded phenotype (two-tailed t-test, P = 0.0066). e, TMB is significantly associated with response in the excluded and inflamed phenotypes (two-tailed t-test, P = 0.00009 and 0.00258, respectively). f, Explained variance in patient response for generalized linear models fit using single core pathways or pathway combinations. In immune desert tumours (n = 57), core pathways showed negligible explanatory power. For excluded tumours (n = 91), F-TBRS and TMB were associated with response as single terms; combining the two provided statistically significant improvement over single terms (likelihood ratio, P = 6.23 × 10 −5 and 0.02125, respectively). For inflamed tumours (n = 56), CD8 + T eff and TMB were associated with response as single terms; combining the two provided statistically significant improvement over single terms (likelihood ratio, P = 0.00099 and 0.0557, respectively). Standard forward selection applied to all patients (grey) identified a threepathway model as a significantly better fit than all single-or two-pathway models (Extended Data Fig. 2g ). * P < 0.05, ** P < 0.01, *** P < 0.001. NS, nonsignificant. For box plots, centre mark is median, whiskers are minimum/maximum excluding outliers, and circles are outliers. Sample sizes are given in parentheses. Lund  TCGA  PD-L1 IC  PD-L1 TC  Response   TMB   TP53  RB1  FGFR3  CDKN2A ERBB2 PIK3CA
UroA GU Inf SCCL UroB
Figure 3 | Relationship between molecular subtypes (Lund scheme)
and core biological pathways. Rows of the heat map show gene expression (Z scores) grouped by pathway. Top right, response versus Lund molecular subtype, showing that the genomically unstable (GU) subtype had a significantly higher response rate (two-sided Fisher's exact test, P = 1.6 × 10 −5 ). Sample sizes are given in parentheses. Inf, infiltrated; SCCL, basal/SCC-like; TC, tumour cells; UroA, urothelial-like A; UroB, urothelial-like B. distribution significantly changed following combination therapy, with mean distance from the stromal border increasing, and mean distance from the tumour centre decreasing. However, T-cell localization did not change with either single antibody treatment ( Fig. 4f-h ; Extended Data Fig. 6f ). Together, these results suggest that TGFβ inhibition potentiated the ability of anti-PD-L1 to enhance anti-tumour immunity, resulting in optimal T cell positioning and ensuing tumour regression.
Anti-TGFβ treatment significantly reduced TGFβ receptor signalling (as shown by the reduction of phosphorylated (p)SMAD2/3) in EMT6 tumours, particularly in non-immune cells (Extended Data Fig. 6g , h). Given that TGFβ is associated with fibroblast differentiation and EMT 22 , we investigated whether the benefits of dual-antibody blockade could be attributed to direct effects on tumour cells or effects on stromal compartments. While single-agent inhibition of TGFβ reduced one of the three EMT signatures that we considered, dual-antibody treatment had no significant impact (Extended Data Fig. 6i ). By contrast, the F-TBRS score and expression of canonical fibroblast genes associated with matrix remodelling were significantly reduced in the combined treatment ( Fig. 4i-l) . Consistent with the phospho-flow analysis that showed no change in pSMAD2/3 in haematopoietic cells, no reduction was observed in two alternate TBRS signatures associated with T cells or macrophages 20 (Extended Data Fig. 6j , k). Blockade of TGFβ can thus synergize with anti-PD-L1 in the EMT6 model to reprogram peritumoural stromal fibroblasts and increase CD8 + T eff cell counts in the tumour bed, leading to robust anti-tumour immunity. Interestingly, 0 5 10 15 20 25 30 35 40   4  8  16  32  64  128  256  512  1,024  2,048  4,096   4  8  16  32  64  128  256  512  1,024  2,048  4,096   4  8  16  32  64  128  256  512  1,024  2,048  4,096   4  8  16  32  64  128  256  512  1,024  2, Letter reSeArCH
although TGFβ inhibition might also be expected to reduce the T reg cell population, we did not observe lower T reg numbers as a result of TGFβ blockade, which therefore did not appear to contribute to the efficacy of the combined treatment.
The comprehensive evaluation of molecular, cellular and genetic factors associated with response and resistance to checkpoint blockade (atezolizumab) in this large cohort of mUC patients has yielded several important conclusions. Three non-redundant factors were found to contribute: (i) pre-existing immunity, as represented by PD-L1 gene expression on immune cells, IFNγ expression and histological correlates of CD8 + T eff activity; (ii) TMB, measured directly (Extended Data Fig. 7 ), but also reflected in signatures of proliferation and DNA damage response; and (iii) TGFβ -pathway signalling, reflected by a distinct gene expression signature and by pSMAD2/3. These tightly linked factors and their relationships with each other may partly explain why predicting outcomes from PD-L1 expression alone is challenging. The enrichment of the fibroblast TGFβ -response signature in nonresponding immune-excluded tumours, combined with results from Lund molecular subtyping and preclinical models showing that coinhibition of TGFβ and PD-L1 converted tumours from an excluded to an inflamed phenotype, support a model in which TGFβ signalling may counteract anti-tumour immunity by restricting the movement of T-cells in the TME. The observed multifactorial basis of response to immunotherapy may be applicable to other tumour types beyond mUC. Work in this area, across multiple tumour types and therapies, is still in its infancy, but these results open new avenues for diseaseagnostic exploration of the mechanisms underlying responses to, and primary immune escape from, cancer immunotherapy.
Code Availability
The source code and processed data used for all analyses presented here have been made available in IMvigor210CoreBiologies, a fully documented software and data package for the R statistical computing environment 29 . This package is freely available under the Creative Commons 3.0 license and can be downloaded from http://research-pub.gene.com/ IMvigor210CoreBiologies.
Data Availability
All raw sequencing data required for RNA-seq analyses have been deposited to the European Genome-Phenome Archive under accession number EGAS00001002556.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Extended Data Figure 1 | Molecular correlates of outcome and TMB. a, Overlap of the efficacy-evaluable patient populations with assays used in this study (n = 326 for one or more of these assays). For gene expression analyses with respect to response, the complete RNA-seq dataset was used (n = 298). For gene expression analyses in the context of TMB or immune phenotype, the intersect between RNA-seq and FoundationOne (FMOne, n = 237) or immune phenotype (n = 244) were used, respectively. For mutation analysis around immune phenotypes, the intersect between FoundationOne and immune phenotype was used (n = 220). For associations between response or genes mutation status with TMB, the complete FoundationOne dataset was used (n = 251). b, PD-L1 protein expression on tumour cells (TC), in contrast to expression on immune cells (Fig. 1a) , was not associated with response to atezolizumab (two-sided Fisher's exact test, P = 0.72). c, d, Transcriptional correlates of PD-L1 protein expression on immune cells. c, Genes associated with PD-L1 immunohistochemistry positivity on immune cells. Normalized log 2 -transformed gene expression was compared with PD-L1 protein expression on immune cells. Interferon-stimulated genes 30 and previously reported CD8 T eff and immune checkpoint-molecule gene sets 4,5 were among the most upregulated (complete list of associated genes is given in Supplementary Table 10 ). d, Association between CD8 T eff -signature score and PD-L1-staining on tumour-infiltrating immune cells. There is a significant positive relationship between the signature score and PD-L1 staining on immune cells (likelihood ratio test, P = 4.2 × 10 −35 ). e, f, Tumour neoantigen burden (TNB) is associated with outcome. e, Box plots showing the relationship between response status and TNB. Shown are the number of mutations based on whole-exome sequencing, filtering for those mutations that are predicted to be expressed neoantigens. TNB is positively associated with response to atezolizumab (two-tailed t-test, P = 2.7 × 10 −9 ). f, TNB, split into quartiles, is also associated with overall survival (likelihood ratio test, P = 0.00015). g, KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways enriched in genes whose expression is correlated with TMB. Shown are adjusted − log 10 P values for enrichment of KEGG gene sets that are significantly (false discovery rate < 0.05) enriched in genes that are correlated with TMB (272 samples analysed). Gene sets that are inferred to reflect key underlying biological processes are coloured. Only the top seven genes per set (ranked by single-gene P value) are shown. ATP5G1 is also known as ATP5MC1, ATP5O is also known as ATP5PO. h, Relationship between different gene-expression signatures as well as the single-gene expression values for MKI67, a marker for proliferation. Dot size and colour show correlation between signature scores and gene expression (348 samples analysed). Numbers are the Pearson correlation coefficients. Gene-set membership is shown in Supplementary Table 8 . i, j, APOBEC3A and APOBEC3B gene expression and their association with response and TMB. Both APOBEC3A (two-tailed t-test, P = 0.015; i) and APOBEC3B (two-tailed t-test, P = 0.0025; j) exhibit higher mean expression in responders. For TMB, Pearson correlation coefficients and P values are given. In j, the two extreme expression outliers were excluded when calculating correlation between gene expression and TMB. k, Mutations in cell-cycle-regulator genes are associated with TMB. Rows represent genes and columns represent patients (n = 293); patients with a mutation are indicated by a black rectangle. The top bar plot depicts TMB in each patient. The final rows represent the mutation status of the pathway with or without TP53. Percentages on the left of the plot indicate prevalence. Genes with significant single-gene associations with TMB are marked by an asterisk. Mutations in cell-cycle-regulator genes are associated with TMB with inclusion of TP53 (two-tailed t-test, P = 4.01 × 10 −8 ), but not without inclusion of TP53 (two-tailed t-test, P = 0.0652156; Supplementary  Table 4 ). l, Mutation status in the cell-cycle-regulation (CCR) pathway by response. For each patient, it is determined whether they have any mutations in genes belonging to the CCR pathway, excluding TP53. Excluding TP53, there is no association between mutation status in the CCR pathway and response (two-sided Fisher's test, P = 0.31104; Supplementary Table 4 ). Sample sizes are given in parentheses. For box plots, centre mark is median, whiskers are minimum/maximum excluding outliers, and circles are outliers. 
Extended Data Figure 2 | Pathways associated with response and cancer-immune phenotypes. a, KEGG pathways are significantly associated with response to atezolizumab (adjusted P < 0.10; comparing 68 responders to 230 non-responders). The top seven genes per set are shown; complete lists are given in Supplementary Table 6 . SGOL1 is also known as SGO1 b, c, IFNG (b) and IFNGR1 (c) gene expression (y axis) are significantly associated with response (two-tailed t-test, P = 9.1 × 10 −5 ) and non-response (two-tailed t-test, P = 0.00012), respectively. d, e, TGFBR2 gene expression (y axis) is significantly associated with nonresponse (two-tailed t-test, P = 0.00019, d) and, when split by quartiles, with reduced overall survival (likelihood ratio test, P = 0.022, e). In b-d, the numbers above the graphs specify sample numbers in each bin. 87 samples per quartile (e). f, Histology of tumour-immune phenotypes desert, excluded, and inflamed. g, Explained variance in patient response. Generalized linear models were fitted to all efficacy-evaluable, immunephenotyped samples (n = 204) using binary response (complete response/ partial response versus stable disease/progressive disease) as the dependent variable and scores from single input or input combinations (x axis) as independent variables. Percentage of explained variance of response is plotted on the y axis. Comparisons between different models were made using a likelihood ratio test. Horizontal bars describe likelihood ratio test results for two-biology versus three-biology model comparisons. Stacked significance symbols for two-biology models show results of likelihood ratio test comparison to the first single-biology model and separately to the second single-biology model, in the same order as the x-axis bar labels; for example, the T eff , TMB model achieves three asterisks when compared to the T eff single model, but an NS when compared to the TMB single model-due to dilution of its inflamed-specific signal in this all-sample analysis. A model that includes both DNA (TMB) and RNA markers (CD8 + T eff signature and F-TBRS) as well as interactions between the F-TBRS and both TMB and cancer-immune phenotype explains 50% of the variance observed in response, and it significantly improves on all single-and two-biology models. This final bar is also given on the far right in Fig. 2f . *P < 0.05, **P < 0.01, ***P < 0.001. NS, P > 0.1. Exact likelihood ratio test P values: T eff ,TBRS versus T eff , 0.0026; T eff ,TBRS versus TBRS, 0.0032; T eff ,TMB versus T eff , 4.9 × 10 −8 ; T eff ,TMB versus TMB, 0.2; TBRS,TMB versus TBRS, 6.6 × 10 −8 ; TBRS,TMB versus TMB, 0.014; T eff ,TBRS,TMB versus T eff ,TBRS, 1.9 × 10 −7 ; T eff ,TBRS,TMB versus T eff ,TMB, 0.0028; T eff ,TBRS,TMB versus TBRS,TMB, 0.016. T eff , CD8 T-effector gene signature. Fig. 3 ). Immune cell and tumour cell PD-L1 status are given. In addition, TMB and mutation status (black, mutated; grey, patients without mutation data) for a few genes of interest are shown. The rows of the heat map show expression (Z scores) of genes of interest, grouped into the following biologies and/or pathways: TCGA, TCGA subtyping genes; A, FGFR3 gene signature; B, CD8 T eff signature; C, antigen-processing machinery; D, immune checkpoint signature; E, MKI67 and cell cycle genes; F, DNA replication-dependent histones; G, DNA damage-repair genes; H, TGFβ receptor and ligand; I, F-TBRS genes; J, angiogenesis signature; K, EMT markers (for details on these signatures see Supplementary Methods) . b, FGFR3-related and WNT target genes 31 as well as PPARG are significantly differentially expressed by Lund subtype (Wald test;
P-values: FGFR3-related, 2.7 × 10 −43 ; WNT target, 1.3 × 10 −15 ; PPARG, 1.2 × 10 −53 ). Gene set membership is given in Supplementary Table 8 . c, d, Distribution of Lund subtypes by cancer-immune phenotypes and response status. c, The fraction of patients within the different Lund subtypes (y axis) is plotted by tumour-immune phenotype. There is a significant difference in Lund-subtype composition between cancerimmune phenotypes (χ 2 test, P = 1.2 × 10 −7 ). d, For excluded tumours, the fraction of patients within the different Lund subtypes (y axis) is plotted by response status. Responders, complete and partial response (CR + PR); non-responders, stable and progressive disease (SD + PD). There is a significant difference in Lund-subtype composition between response groups (χ 2 test, P = 0.00061). The numbers above the graphs specify sample numbers in each bin. e, Assessment of MKI67 expression and signatures of interest as well as TMB relative to molecular subtypes. Biologies of interest were scaled before medians were calculated across the Lund (left) and TCGA (right) molecular subtypes (columns). Red, high; blue, low. DNA rep., DNA replication. Tumours were collected 14 days after inoculation, flash-frozen and lysed for protein quantification (n = 4 mice; data from one experiment). g, BALB/cJ mice were inoculated orthotopically with EMT6 tumour cells. When tumour volumes reached around 160 mm 3 approximately nine days after inoculation, mice were treated with isotype control, anti-PD-L1, anti-TGFβ , or a combination of anti-PD-L1 and anti-TGFβ . Tumours were measured two times per week for approximately eight weeks by calliper. When tumour volumes fell below 32 mm 3 (lowest limit of detection), they were considered complete response. Percentage of complete regressions across 2-6-independent studies (10 mice per group per study). h, Tumour weights at day seven after initiation of treatment (n = 28 mice per treatment group; data from three independent experiments).
i, CD8 depletion experiment. CD8 T cells were depleted before initiation of treatment (n = 10 mice per group, data from one experiment). j, Quantification of TGFβ and PD-L1 RNA in whole MC38 tumours by RNA-seq. The tumours were inoculated subcutaneously and collected when volume reached 300 mm 3 (n = 5 mice; data from one experiment). k, Quantification of CD8 T cells in the centre and in the periphery of EMT6 and MC38 tumours from immunohistochemistry stains. Data expressed as number of cells per tissue area (periphery is defined as 400-600 μ m from the tumour edge, centre is the remaining distance to the centre point). EMT6, n = 5 mice; MC38, n = 4 mice. i, Collagen (green) and T cells (CD3, red) in MC38 tumours stained by immunofluorescence. Scale bar, 1 mm (left); 0.1 mm (right, representative images of 5 biological replicates). m, C57BL/6 mice were inoculated subcutaneously with MC38 tumour cells. When tumour volumes reached around 180 mm 3 approximately eight days after inoculation, mice were treated with isotype control, anti-PD-L1, anti-TGFβ , or a combination of anti-PD-L1 and anti-TGFβ . Tumours were measured two times per week for approximately eight weeks by calliper. When tumour volumes fell below 32 mm 3 (lowest limit of detection), they were considered complete response. Percentage of complete response across two independent studies (one for anti-TGFβ alone) shown with 10 mice per treatment group for each independent study. n, Tumour growth curves for each individual mouse are shown. The data are representative of two independent experiments with 10 mice per treatment group. For box plots, centre mark is median, and whiskers are minimum and maximum. All statistics are two-sided Mann-Whitney U-tests compared to isotype group. *P < 0.05, **P < 0.01, ***P < 0.001. 
Extended Data Figure 6 | Changes in TME following anti-TGFβ + anti-PD-L1 treatment in EMT6 tumours. a, c, d, Cytofluorimetric analysis of T cells seven days after initiation of the treatment. The abundance of total T cells (a), total CD4 + cells (c) and the percentage of T-regulatory cells (CD25 + FOXP3 + ) in the CD4 + population (d) are shown. n = 15 mice for all treatment groups except for anti-TGFβ alone in which n = 10; data combined from three independent experiments expressed as fold change relative to the isotype mean. b, e, RNA-seq analysis on whole tumours collected seven days after the initiation of treatment. Single-gene expression for Ifng, Gzmb and Zap70 (b) Ikzf2 (also known as Helios) and Foxp3 (e) are shown (n = 8 mice per treatment group; data from one experiment). f, Distribution of tumour-infiltrating lymphocytes in tumours as assessed by immunohistochemistry and digital imaging seven days after the initiation of treatment as above. Representative CD3 staining (brown). Dashed line indicates tumour boundaries. (n = 19 for all groups except anti-PD-L1/anti-TGFβ , in which n = 20; three independent experiments). Scale bar, 500 μ m. g, Quantification of pSMAD2 by immunohistochemistry at day seven after initiation of treatment. (n = 9 or 10 mice per treatment group; data from one experiment). h, Phosphoflow analysis of SMAD2/3 in tumours seven days after the initiation of treatment as above. MFI of pSMAD2/3 among total cells, CD45 − or CD45 + cells are shown. Data are expressed as fold change (FC) relative to the isotype MFI average. Ten mice per treatment group from two independent experiments. i-k, RNA-seq analysis on whole tumours collected seven days after the initiation of treatment. Three EMT signatures (i), and TGFβ -response signatures for T cells (j) and macrophages (k) are also shown. (n = 8 mice per treatment group; data from one experiment). All statistics in the figure use two-sided Mann-Whitney U-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, not significant compared to isotype group. 33 and EMT3 34 , are significantly higher in non-responders (stable and progressive disease) than in responders (complete and partial response) in excluded tumours (EMT1, P = 0.0102; EMT2, P = 0.0027; EMT3, P = 0.0063); there is no significant difference in signature scores in desert and inflamed tumours (all P = 1;
two-tailed t-test, P values for each signature are Bonferroni-corrected for three tests). The numbers above the graphs specify sample numbers in each bin. c, Explained variance in patient response. Generalized linear models were fitted using binary response (complete or partial response versus stable or progressive disease) as the dependent variable and scores from single input or input combinations (x axis) as independent variables (233 samples). Percentage of explained variance of response is plotted on the y axis. Comparisons between different models were made via likelihood ratio test; a significant P value means that the additional variable contributed some independent information to the model. The association of F-TBRS with response is the strongest among its correlates, that is, three different EMT signatures. None of these signatures provided additional explanatory information independent of F-TBRS.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Our analyses were performed on samples from participants of a clinical trial with predetermined in-and exclusion criteria. We show in Extended Data table S9 that the biomarker evaluable population was equivalent in important covariates to the original intent-to-treat population. Grouping of samples in our analyses were based on objective phenotypes, such as response.
For assessing treatment effect in mice, these were grouped using the "Gould-Hanson with Chan modification Grouping Algorithm" as follows: (Step 1) Determine average volume and remove any ungrouped animals based on their deviation from the average; (Step 2) Sort list of animals by alternating descending deviant high and low volumes (H3,L3,H2,L2,H1,L1); (Step 3) Assign to groups based on even or odd number of groups (to create even distribution): (i) Odd # of groups, in straight sequential (1,2,3,4,5,1,2,3,4,5...etc) and (ii) Even # of groups, in snaking-sequential (1,2,3,4,4,3,2,1…etc); (Step 4) All groups are assigned sequentially with the other groups until all animals in that group are assigned, i.e. larger groups will have the least variation in the extra animals)
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not relevant as all subjects received the same treatment. All data was analyzed computationally only (no subjective data interpretation).
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Analyses were mostly performed using standard software, such as FlowJo for FACS, Matlab/Mathworks for imaging data, GraphPad and the statistical programming language R. Human data were analyzed using functionality of software packages available at Bioconductor. The methods section gives a very detailed description of individual analysis steps for both human and mouse data. In addition, a data and analysis code package will be made available enabling the reproduction of all data presented in the manuscript. This package will also include statistical outputs from GraphPad.
